• LAST PRICE
    13.3200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    11.0000/ 5
  • Ask / Lots
    29.4000/ 3
  • Open / Previous Close
    0.0000 / 13.3200
  • Day Range
    ---
  • 52 Week Range
    Low 11.0000
    High 26.6000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 13.17
TimeVolumeAADI
09:53 ET76013.33
09:55 ET20013.33
10:11 ET30013.38
10:15 ET10013.4
10:18 ET40013.385
10:20 ET65013.3
10:22 ET10013.255
10:29 ET28413.35
10:31 ET20213.36
10:33 ET164913.3
10:36 ET10013.28
10:38 ET35013.36
10:45 ET30013.305
10:58 ET356413.3
11:00 ET60013.3
11:02 ET30013.3
11:07 ET10013.32
11:09 ET80013.26
11:12 ET20013.26
11:32 ET40013.3
11:34 ET40013.28
11:39 ET120013.3
11:41 ET100013.325
11:52 ET10013.3
11:54 ET10513.3
12:14 ET20013.31
12:19 ET10013.33
12:26 ET10013.3
12:33 ET15013.2922
12:44 ET171013.275
12:50 ET94813.29
12:51 ET100013.38
12:55 ET23113.33
01:00 ET89513.32
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAADI
Aadi Bioscience Inc
324.9M
-4.5x
---
United StatesHUMA
Humacyte Inc
326.9M
9.6x
---
United StatesPRLD
Prelude Therapeutics Inc
326.4M
-2.7x
---
United StatesOMGA
Omega Therapeutics Inc
321.9M
-3.5x
---
United StatesALDX
Aldeyra Therapeutics Inc
319.7M
-4.9x
---
United StatesOCGN
Ocugen Inc
330.5M
-4.3x
---
As of 2022-11-28

Company Information

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company, The Company is engaged in developing precision therapies for genetically-defined cancers. The Company’s primary focus is to bring transformational therapies to cancer patients with mechanistic target of rapamycin (mTOR) pathway driver alterations such as alterations in TSC1 or TSC2 genes. The Company’s initial focus is the treatment of an ultra-rare cancer perivascular epithelioid cell tumor (PEComa). The Company’s lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).

Contact Information

Headquarters
17383 Sunset Avenue, Suite A250PACIFIC PALISADES, CA, United States 90272
Phone
424-473-8055
Fax
302-655-5049

Executives

Executive Chairman of the Board
Neil Desai
Chief Financial Officer, Treasurer
Scott Giacobello
President, Chief Executive Officer, Director
Brendan Delaney
Chief Medical Officer
Loretta Itri
Independent Director
Behzad Aghazadeh

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$324.9M
Revenue (TTM)
$11.0M
Shares Outstanding
24.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.27
EPS
$-2.97
Book Value
$6.53
P/E Ratio
-4.5x
Price/Sales (TTM)
29.6
Price/Cash Flow (TTM)
---
Operating Margin
-574.71%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.